Drug absorption from nifedipine hydrophilic matrix extended-release (ER) tablet - comparison with an osmotic pump tablet and effect of food

Journal of Controlled Release

Volumn 52, Issue 3, 1998, Pages 301-310

  Abrahamsson, Bertil ^a   Alpsten, Magne ^b   Bake, Björn ^b   Jonsson, Ulf E ^a   Eriksson Lepkowska, Maria ^a   Larsson, Annhild ^b  

^a ASTRAZENECA R AND D   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Bioavailability; Extended release; Food effects; Gammascintigraphy; Nifedipine

Indexed keywords

NIFEDIPINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; FOOD DRUG INTERACTION; GAMMA SCINTIGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; SUSTAINED RELEASE FORMULATION; TABLET;

ADULT; BIOLOGICAL AVAILABILITY; DELAYED-ACTION PREPARATIONS; HUMANS; MALE; NIFEDIPINE; OSMOSIS; REFERENCE VALUES; TABLETS;

EID: 0032584121     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(97)00267-8     Document Type: Article

References (22)

1. Grundy J.S., Foster R.T. The nifedipine gastrointestinal therapeutic system (GITS), evaluation of pharmaceutical, pharmacokinetic and pharmacological properties. Clin. Pharmacokin. 30:1996;28-51.
2. 12C-nifedipine. Eur. J. Pharmacol. 50:1996;195-201.
3. Kleinbloesem C.H., van Brummelen P., Danhof M., Faber H., Urquhart J., Breimer D.D. Rate of increase in the plasma concentration of nifedipine as a major determinant of its haemodynamic effects in humans. Clin. Pharmacol. Ther. 41:1987;26-30.
4. Murdoch D., Brogden R.N. Sustained release nifedipine formulations: an appraisal of their current uses and prospective roles in the treatment of hypertension, ischaemic heart disease and peripheral vascular disorders. Drugs. 41:1991;737-779.
5. Alderman D.A. A review of cellulose ethers in hydrophilic matrices for oral controlled-release dosage forms. Int. J. Pharm. Tech. Prod. Manufact. 5:1984;1-9.
6. Swanson D.R., Barclay B.L., Wong P.S.L., Theeuwes F. Nifedipine gastrointestinal therapeutic system. Am. J. Med. 83(Suppl. 6B):1987;3-9.
7. Abrahamsson B., Alpsten M., Hugosson M., Jonsson U.E., Sundgren M., Svenheden A., Tölli J. Absorption, gastrointestinal transit and tablet ersoion of felodipine extended-release (ER) tablets. Pharm. Res. 5:1993;709-714.
8. Anhoff M. Determination of felodipine in plasma by capillary gas chromatography with electron capture detection. J. Pharm. Biomed. Anal. 2:1984;519-526.
9. Wagner J.G., Nelson W. Percent absorbed time plots derived from blood level and/or urinary excretion data. J. Pharm. Sci. 52:1963;610-611.
10. Foster T.S., Hamann S.R., Richards V.R., Bryant P.J., Graves D.A., McAllister R.G. Jr. Nifedipine kinetics and bioavailability after single intravenous and oral doses in normal subjects. J. Clin. Pharmacol. 23:1983;161-170.
11. Langenbucher F. Numerical convolution/deconvolution as a tool for correlating in vitro with in vivo drug availability. Pharm. Ind. 44:1982;1166-1172.
12. Grundy J.S., Grace D.W., Foster R.T. Observation of time-dependent and variable subject kinetics in a nifedipine gastrointestinal therapeutic system bioequivalence study. J. Control. Release. 44:1997;247-254.
13. Höllt V., Kouba M., Dietel M., Vogt G. Stereoismers of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulation drug transport by P-glycoprotein. Biochem. Pharmacol. 43:1992;2601-2608.
14. Raemsch K.-D., Sommer J. Pharmacokinetics and metabolism of nifedipine. Hypertension. 5:1983;II18-II24.
15. Melander A., McLean A. Influence of food on presystemic clearance of drugs. Clin. Pharmcokin. 8:1983;286-296.
16. Hirasawa K., Shen W.F., Kelly D.T., Roubin G., Tateda K., Shibata J. Effect of food ingestion on nifedipine absorption and haemodynamic response. Eur. J. Clin. Pharmacol. 28:1985;105-107.
17. Reitberg D.P., Love S.J. Effect of food on nifedipine pharmacokinetics. Clin. Pharmacol. Ther. 42:1987;72-75.
18. Challenor V.F., Waller D.G., Gruchy B.S., Renwick A.G., George C.F. Food and nifedipine pharmacokinetics. Br. J. Clin. Pharm. 23:1987;248-249.
19. Sorkin E.M., Clissold S.P., Brogden R.N. Nifedipine - A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in ischaemic heart disease, hypertension and related cardiovascular disorders. Drugs. 30:1985;182-274.
20. Chung M., Reitberg D.P., Gaffney M., Singleton W. Clinical pharmacokinetics of nifedipine gastrointestinal therapeutic system: A controlled-release formulation of nifedipine. Am. J. Med. 83(Suppl. 6B):1987;10-14.
21. Davis S.S., Washington N., Parr G.D., Short A.H., John V.A., Lloyd P., Walker S.M. Relationship between the rate of appearance of oxprenolol in systemic circulation and the location of an oxprenolol Oros 16/260 drug delivery system within the gastrointestinal tract as determined by scintigraphy. Br. J. Clin. Pharmacol. 26:1988;435-443.
22. Wilson C.G., Washington N., Greaves J.L., Kamali F., Rees J.A., Sempik A.K., Lampard J.F. Bimodal release of ibuprofen in sustained-release formulation: a scintigraphic and pharmacokinetic open study in healty volunteers under different conditions of food intake. Int. J. Pharm. 50:1989;155-161.